This study demonstrates the potential of salivary biomarkers as a non-invasive diagnostic approach for metastatic PTC to aid the appropriate dosing for RAI therapy. It also offers new insights into the mechanisms of PTC metastasis and potential targets for adjuvant therapy.
Yu et al. (Thu,) studied this question.